F. Hoffmann-La Roche Ltd: European Commission approves Roche

F. Hoffmann-La Roche Ltd: European Commission approves Roche's fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

F. Hoffmann-La Roche Ltd: European Commission approves Roche's fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Related Keywords

Canada , Australia , Japan , Melbourne , Victoria , United States , Switzerland , America , Sileia Urech , Gerard Tobin , Birgit Masjost , Sabine Borngr , Bruno Eschli , Michael Dickinson , Loren Kalm , Nathalie Altermatt , Karsten Kleine , Levi Garraway , Kirti Pandey , Roche Group , European Medicines Agency Summary Of Product Characteristics , Peter Maccallum Cancer Centre , European Commission , World Health Organization , Genentech , Roche Group Media Relations , Head Of Global Product Development , Chief Medical Officer , Global Product , Associate Professor , Royal Melbourne Hospital , New England Journal , Fixed Duration Columvi , Drug Administrationcolumvi , Dow Jones Sustainability Indices , Chugai Pharmaceutical , European Medicines Agency Summary , World Health , Cancer Incidence , Refractory Diffuse Largeb Cell , Ihre Watchlist ,